|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on May 31, 2002; DOI 10.1182/blood-2002-01-0248.
CHEMOKINES
From the Joint Program in Transfusion Medicine, Harvard
Medical School, Children's Hospital Boston, MA, and the James Graham
Brown Cancer Center, University of Louisville, KY.
Although the SDF-1 (CXCL12)/CXCR4 axis is important for
B-cell development, it is not yet clear to what extent CC chemokines might influence B lymphopoiesis. In the current study, we characterized CC chemokine receptor 5 (CCR5) expression and function of primary progenitor B-cell populations in human bone marrow. CCR5 was expressed on all bone marrow B cells at levels between 150 and 200 molecules per
cell. Stimulation of bone marrow B cells with the CCR5-binding chemokine macrophage inflammatory protein 1 Chemokines were initially defined as molecules
abundantly produced at sites of inflammation and responsible for the
recruitment of cells to participate in local immune
responses.1 Indeed, chemokines have been shown to direct
the movement of cells between intravascular and extravascular
compartments, within specific zones of secondary lymphoid organs, and
to drive cells to recirculate between tissues and lymphoid
organs.2,3 It has recently become clear that this family
of molecules also controls multiple cell functions involving
angiogenesis, embryogenesis, lymphocyte development, and
hematopoiesis.4,5
The growth and differentiation of progenitor B cells are dependent on
factors such as chemokines and cytokines, which are either bound or
secreted by bone marrow stromal cells.6 Within the
extravascular compartment of bone marrow, there are several well-known
movements of progenitor B cells in which chemokines might be involved.
The earliest progenitor B cells (eg, pro-B cells), are located within
or near the endosteum.7,8 In subsequent stages of
development, the differentiating B cells move toward sinusoids along
stromal cell processes.8,9 After beginning to express
surface IgM (sIgM), the immature and mature B cells migrate into the
sinusoid segments and are released into the circulation.
The CXCL12/CXCR4 axis appears essential for B-cell development during
early ontogeny. Mice in which the gene for CXCR4 or CXCL12 is disrupted
show impaired B lymphopoiesis in the bone marrow.10,11 In
other experiments, the transfer of CXCR4-deficient stem cells into
wild-type mice results in high circulating levels of progenitor B
cells, suggesting that the CXCL12/CXCR4 axis is important for the
retention/positioning of early-lineage B cells in the bone marrow
cavity.12,13 Furthermore, in support of this hypothesis is
the observation that in both mice and humans CXCL12-mediated
responsiveness decreases with B-cell maturation, despite comparable
high levels of CXCR4 expression at all developmental B-cell
stages.14-16 In contrast, little data are available as to the role of CC chemokine receptors during B-cell development. We
reasoned that CC chemokines and corresponding receptors might also
participate in the positioning of progenitor B cells in the bone marrow.
In the current study we therefore characterized CCR5 expression and
function on primary progenitor B-cell populations (pro-, pre-,
immature, and mature B cells) in human bone marrow. Cell surface
expression of CCR5 on all bone marrow B cells was low compared with
CXCR415 and calculated to be between 150 and 200 molecules
per cell. Although CCL4 did not elicit chemotaxis of bone marrow B
cells, CCL4 was capable of triggering potent calcium mobilization
responses of pro-B and pre-B cells and mitogen-activated protein kinase
(MAPK) activation of all progenitor B-cell populations. Moreover, we
determined that CCL4 as well as other CCR5 ligands (ie, CCL3 and CCL5)
could desensitize primary bone marrow B cells to subsequent
CXCR4/CXCL12-mediated calcium mobilization, extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) and p38 phosphorylation as well as chemotaxis responses. We also established that this inhibitory effect was dependent on the specific interaction of these
chemokines with CCR5. To our knowledge, the present data represent the
first example of heterologous desensitization of CXCR4 by signaling
through CCR5.
Thus, CCR5-binding chemokines can trigger biologically significant
responses of bone marrow B cells. The negative regulation of the
CXCL12/CXCR4 axis by CCL4 may be important in the migration of
progenitor B cells within the bone marrow compartment prior to their
egress into the circulation.
Cells
Isolation of total RNA and RT-PCR of CCR5 chemokine
receptor
The following primers were synthesized by Gibco BRL (Grand Island, NY). For CCR5, sense primer sequence was 5'-GTTTGCGTCTCTCCCAGGAATCA-3' and antisense primer was 5'-CTTGCTCGCTCGGGAGCCTCTT-3'. The product length was 600 bp. For control gene GAPDH, sense primer was 5'-GGTGAAGGTCGGAGTCAACG-3' and antisense primer was 5'-CAAAGTTGTCATGGATGACC-3'. The product length from cDNA was 500 bp. The conditions for amplification were 5 minutes at 94°C, followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 62°C, 40 seconds at 72°C, followed by an extension for 4 minutes at 72°C. PCR products were resolved by electrophoresis on 1.2% agarose gels and visualized by the ethidium bromide staining. The appropriate length of the GAPDH product and the lack of a detectable band in the control without reverse transcriptase (no-RT), indicated that there was no contamination of gDNA. Antibodies Surface staining of bone marrow cells was performed with the following antibodies (all from Pharmingen, San Diego, CA, unless otherwise stated): fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-labeled anti- light chain, FITC- or PE-labeled anti- light chain, PE-labeled anti-CD19, Cy-chrome-labeled anti-CD19,
Cy-chrome-labeled anti-CD34, FITC- or PE-labeled anti-IgD, Red
613-labeled anti-CD19 (Caltag Laboratories, Burlingame, CA),
allophycocyanin (APC)-labeled anti-CD19 (Caltag Laboratories),
PE-labeled anti-CCR5 antibody (clone 2D7).
The secondary antibody was goat antimouse IgG-Cy5 labeled (Jackson Immunoresearch Laboratories, West Grove, PA). Nonconjugated mouse monoclonal antibodies were anti-CCR5 clone 2D7, clone 45529 (R & D Systems, Minneapolis, MN), anti-CXCR4 antibody (clone 12G5; R & D Systems). Cell surface staining of bone marrow B cells Four stages of B-cell differentiation were isolated from bone marrow cells as previously described.15 The earliest B-cell population, designated here as pro-B cells, was /, CD19+,
CD34+. The next developmental B-lineage populations were
designated as pre-B cells, identified as
/, CD19+,
CD34; followed by immature B cells identified as
+/+, CD19+,
IgD; and mature B cells identified as
+/+, CD19+, IgD+.
Cell sorting The Ficoll-Hypaque-purified bone marrow cells were suspended in ice-cold staining buffer (1 times PBS, 2% FBS) and incubated for 30 minutes with monoclonal antibodies. Cells were washed 3 times and resuspended in buffer (1 times PBS, 0.5% FBS).The sorting into highly purified populations was performed on a MoFlo sorter (Cytomation, Fort Collins, CO) with the purity being more than 98.5%. Cell surface staining for CCR5 Five-color immunofluorescence analysis was used to examine the expression of chemokine receptors on the surface of different B-cell populations. The different subsets of B cells were identified as described above. The fifth channel was used to define cell surface expression of CCR5. Ten thousand events were acquired in the fifth channel after triple gating for B-cell subsets. The threshold line was based on the maximum staining of a matched isotypic antibody with irrelevant specificity (mouse IgG2a) used in the same concentration as the anti-CCR5 antibody (4 µg/50 µL staining buffer). CCR5 cells were defined such that less than 1%
of cells stained positive with control antibodies. Anti-CCR5-labeled
cells that were brighter than those stained with the isotypic antibody
(present to the right of isotype control histogram) were defined as
positive for CCR5.
Data were acquired using a MoFlo flow cytometer (Cytomation) and analyzed with WinMDI 2.8, kindly provided by Dr Joseph Trotter (Scripps Research Institute, La Jolla, CA), or Summit (Cytomation) software. QFACS Quantitative flow cytometric analysis (QFACS) was performed by converting the mean fluorescence intensity of the cell subset into antibody-binding sites (ABSs) using a standardized microbeads kit (Sigma, St Louis, MO).Beads (105/sample) were incubated with the same saturating concentration of 2D7-PE-labeled anti-CCR5 antibody (Pharmingen) as the samples and processed identically to those being quantified. The binding capacities of the stained beads were then regressed against the corresponding geometric mean of each bead population. The mean fluorescence intensity of CCR5 staining of the cells was converted to ABSs per cell. The mean fluorescence intensity of the isotype control (68-70 ABSs) for each B-cell subset also was converted to ABSs and subtracted from ABS values obtained with the experimental sample. The threshold of detection was 110 ABSs per cell. Additional details on the relationship between ABSs and mean fluorescence intensity values can be obtained from the manufacturer (Sigma). Measurement of calcium signaling using FACS Cells used in the calcium flux assay were stored overnight at 37°C in serum-free medium (StemSpan H2000, Stem Cell Technologies, Vancouver, BC, Canada).Cells were suspended in 1 mL 30°C Hanks balanced salt solution containing 1.3 mM CaCl2, 0.5 mM MgCl2, 1 µM Indo-1AM (Molecular Probes, Eugene, OR), and 0.01% F-127 Pluronic detergent (Molecular Probes) and incubated for 45 minutes at 30°C. After stimulation with 1000 ng/mL CCL4 (R & D Systems) or 100 ng/mL CXCL12 (kindly provided by Dr Bill Holmes, GlaxoWellcome, Research Triangle Park, NC), calcium mobilization was analyzed with a Becton Dickinson FACStar Plus flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA) equipped with Time Zero Injection Module (Cytek, Fremont, CA). UV excitation wavelengths were 350 to 364 nm, emission 405 nm and 510 nm. Cells were incubated at 37°C for 5 minutes before analysis. Chemotaxis assay Total bone marrow Ficoll-purified lymphocytes were stored overnight at 37°C in serum-free medium (StemSpan H2000) to remove adherent cells. Total lymphocytes were put into the upper well (106 cells/well) of Transwell inserts (6.5 mm diameter, 5 µm filter pore size; Costar, Cambridge, MA); the lower well contained 600 µL serially diluted (1-10 000 ng/mL) CCL4 or, as a positive control, 100 ng/mL CXCL12 (all from Peprotech, Rocky Hill, NJ) in 0.5% bovine serum albumin (BSA), RPMI 1640.Cells were allowed to migrate for 2 to 4 hours at 37°C. Cells that passed through the membrane to the lower well were collected and stained with antibodies to B-cell determinants, as described above. Cells were counted by timed acquisition (120 seconds each sample, at 2 psi sample pressure differential) on a MoFlo flow cytometer (Cytomation). CCR5-mediated inhibition of CXCL12-induced chemotaxis The Ficoll-purified lymphocytes (106 cells in 0.5% BSA, RPMI-1640) along with 1000 ng/mL CCL3, CCL4, CCL5, macrophage inflammatory protein 3 (MIP-3; CCL19), MIP-3 (CCL20), or BCA-1
(CXCL13; all from Peprotech) were placed into the upper well of
Transwell inserts (6.5 mm diameter, 5 µm filter pore size; Costar).
The lower well contained either 600 µL 100 ng/mL CXCL12 or 600 µL 100 ng/mL CXCL12 together with 1000 ng/mL CCL3, CCL4, CCL5, CCL19, CCL20, or CXCL13 in 0.5% BSA, RPMI 1640. The cells were allowed to
migrate for 15 or 30 minutes.
To determine if CCL4-induced inhibition of CXCL12 chemotaxis was concentration dependent, increasing concentrations of CCL4-1, 10, 100, 1000, and 10 000 ng/mL were placed in both upper and lower wells, whereas 100 ng/mL CXCL12 was present in the lower well. To assess whether inhibition of chemotaxis to CXCL12 was specific for CCL4, we used the following controls: (1) 1000 ng/mL heat-denatured CCL4 (boiled for 10 minutes at 100°C), (2) 1000 ng/mL CCL4 preincubated for 30 minutes with CCL4 neutralizing antibody (40 µg; R & D Systems), (3) cells were preincubated at 37°C with 1000 ng/mL CCL4 for 30 minutes before placement into upper well; this latter measure causes internalization of CCL4-binding chemokine receptors, thus abrogating the inhibition of CXCL12-mediated chemotaxis. We also used controls to assess whether inhibition of CXCL12-induced chemotaxis was CCR5 dependent. Lymphocytes were preincubated for 30 minutes with either: (1) 10 µg/mL isotype control antibody (IgG2a, Pharmingen); (2) 10 µg/mL nonneutralizing anti-CCR5 monoclonal antibody (clone 45529, recognizing the second half of the second extracellular loop of the CCR5 receptor17; R & D Systems); or (3) 10 µg/mL neutralizing anti-CCR5 monoclonal antibody (clone 2D7, recognizing the first half of the second extracellular loop of the CCR5 receptor17; Pharmingen). The lymphocytes were subsequently placed into the upper well (106 cells/well) of Transwell inserts along with 1000 ng/mL CCL4. The lower well contained 600 µL 100 ng/mL CXCL12 along with 1000 ng/mL CCL4 in 0.5% BSA, RPMI 1640. The cells were allowed to migrate for 15 minutes. Cells that passed through the membrane to the lower well were collected, stained with antibodies to B-lineage determinants and analyzed as described above. Influence of CCL4 on the expression of CXCR4 To detect internalization of CXCR4, cells were incubated for 30 minutes at 37°C with 100, 1000 ng/mL CCL4 or 1000 ng/mL CXCL12 (Peprotech). After incubation, cells were immediately put on ice to prevent resurfacing of the receptor and stained with anti-CXCR4 antibody (clone 12G5; R & D Systems) as described above.Western blotting Early- and late-lineage B cells were stimulated with medium alone, 1000 ng/mL CCL4, 100 ng/mL CXCL12 or prestimulated first with 1000 ng/mL CCL4, and then after 5 minutes, stimulated with 100 ng/mL CXCL12. Stimulations were done for 2 minutes at 37°C. The reactions were stopped by adding ice-cold PBS. Protein samples were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). Membranes were blocked in 5% BSA/Tris-buffered saline (TBS)-Tween 20 buffer and sequentially incubated with 0.5 µg/mL antiphospho-ERK1/2 or antiphospho-p38 antibodies (New England Biolabs) at 4°C for 3 hours, followed by incubation with horseradish peroxidase (HRP)-conjugated goat antirabbit antibody for 1 hour and subsequently developed using an enhanced chemoluminescence (ECL) kit (Amersham Pharmacia Biotech, Uppsala, Sweden). Membranes were then stripped with 1 times stripping buffer (Chemicon, Temecula, CA) and reblotted with anti-ERK1/2 or anti-p38 antibodies to verify the amount of proteins on the gels. The intensity of phosphoprotein was determined by densitometry using ImageQuant Version 1.1 (Molecular Dynamics, Sunnyvale, CA).Enzyme-linked immunosorbent assay for detection of chemokines Secretion of MIP, CCL3, CCL4, regulated on activation, normal T cell-expressed and -secreted protein CCL5, monocyte chemoattractant protein (MCP-1; CCL2), and Eotaxin (CCL11) was detected by Quantikine Human Immunoassay (R & D Systems), according to the manufacturer's protocol. Briefly, FACS-sorted early- (pro/pre combined) and late- (immature/mature combined) lineage B cells were cultured for 24 hours in serum-free medium (StemSpan H2000) at the concentration of 106 cells/1 mL medium. Conditioned media derived from cells were analyzed by the quantitative sandwich enzyme immunoassay.
Expression of CCR5 on different subsets of primary B cells from bone marrow The percentage of CCR5+ cells measured by 2D7 antibody staining is shown (Figure 1). CCR5 expression was next evaluated by RT-PCR as well as by determining the number of anti-CCR5 binding sites per cell (Figure 1). Due to limitations in cell number, the sum of anti-CCR5 binding sites was calculated on a cell population designated as early lineage or late-lineage B cells. This early lineage B-cell population included both pro-B and pre-B cell subsets (CD19+,/) and late lineage B-cell population
included both immature and mature B cells (CD19+,
+/+).
The number of anti-CCR5 binding sites per cell was comparable for all stages of B-cell development in bone marrow (mean ± SD, n = 4): 165 ± 40 for early lineage (pro/pre) B cells, and 193 ± 67 for late lineage (immature/mature) B cells. Both by flow cytometry as well as QFACS, the level of CCR5 expression on progenitor B cells is lower than previously reported for CXCR4.15 CCL4-induced responses of developmental B-cell populations Chemokine receptors may still be biologically functional, even though they are expressed at relatively low levels on the cell surface.18 Thus, we assessed calcium mobilization responses of B-lineage cell subsets sorted from bone marrow after stimulation with 1000 ng/mL CCL4 (Figure 2A).
Sixty percent of pro-B cells showed an agonist-dependent calcium response to CCL4, appearing 30 seconds after stimulation and returning to base level after 2 to 3 minutes. Most of the pre-B cells (94% cells) showed increased calcium mobilization responses after addition of CCL4, with kinetics similar to those observed for pro-B cells. In contrast, mature B cells showed a low calcium mobilization response to CCL4 (only 2%-7% of stimulated cells responded; data not shown). Different B-cell subsets were also stimulated sequentially, first with CXCL12 and subsequently with CCL4. As a control, another aliquot of bone marrow B cells sorted from the same donor was stimulated first with CCL4 and subsequently restimulated with CXCL12 (Figure 2B). Because CXCL12 and CCL4 are believed to bind specifically to CXCR4 and CCR5 receptors, respectively, we did not expect any cross-influence as measured by the calcium response. As indicated in Figure 2B, pre-B cells exhibited a robust calcium response after stimulation with CXCL12, as well as after restimulation with CCL4. In contrast, when pre-B cells were first stimulated with CCL4, the subsequent response to CXCL12 did not cause an increase in intracellular calcium concentration. It is possible that the lack of calcium response to a second, subsequent ligand may be caused by depletion of the intracellular calcium stores. However, our measurements of Indo-1AM cell loading after 2 consecutive stimulations are consistent with adequate calcium reserves. Further, when CCL4 follows CXCL12 stimulation, a vigorous sustained calcium response is seen, which indicates adequacy of calcium stores. Chemotactic responses of different B-cell subsets toward CCL4 In view of the robust calcium responses of early B cells to CCL4 stimulation, we examined whether this chemokine could also elicit the migration of bone marrow B cells.To avoid the influence of cell stress factors (ie, cell sorting), total
bone marrow cells were loaded into Transwell and the migrated cells
were then stained with appropriate markers to define B-cell subsets, as
described in "Materials and methods." CCL4 did not cause chemotaxis
of pro-B, pre-B, immature, or mature B cells. The migration was tested
along a wide range of chemokine concentrations (1-10 000 ng/mL; 0.125 nM to 1.25 µM) and sufficient time was allowed for the cells to
migrate (2-4 hours). The number of cells, which migrated in the
presence of CCL4, however, was not significantly different than
spontaneous migration in the presence of medium alone (negative
control; Figure 3).
For comparison, the known migration responses of bone marrow B cells to
CXCL1214-16 are shown thus indicating their potential of
chemotaxis. To confirm the biologic activity of CCL4 used in our
assays Inhibition of CXCL12-induced chemotaxis of bone marrow B cells mediated by CCR5 binding chemokines Our finding that stimulation with CCL4 inhibited CXCL12-induced calcium responses prompted our examination of whether this phenomenon could be extended to a more complex biologic event, such as cell migration requiring the activation of multiple downstream signaling pathways. Thus, we examined if exposure of bone marrow B cells to 1000 ng/mL CCL4 could inhibit their migration toward CXCL12. The experiments were performed with CCL4 present only in the upper well of the Transwell system or with the chemokine present in both upper and lower wells of the chemotaxis chamber.When CCL4 was added only to the upper well of the Transwell system, a
considerable inhibition of migration toward CXCL12 was observed. This
inhibition is expressed as the percent migration of CCL4-treated cells
relative to the migration of untreated cells to CXCL12 (Figure
4Ai). Where the migration of untreated
cells to CXCL12 was considered to be 100%, the percent migration
(mean ± SD, n = 6) of CCL4-treated pro-B, pre-B, immature, and
mature bone marrow B cells was 42% ± 16%, 43% ± 10%, 33% ± 14%, and 51% ± 16%, respectively. In all cases the number of
migrated cells was sufficiently high for reliable statistical analysis
(see below).
Some chemokines have the ability to cause nonspecific movement of stimulated cells (chemokinesis) or cause movement away from the chemokinetic agent (repulsion).19 These phenomena may have biased the observed CCL4-mediated inhibition of chemotaxis to CXCL12. To test for this possibility, we added CCL4 at the same concentration to both upper and lower wells to ensure that there was no dynamic gradient of CCL4 present between the wells. In these experiments, CCL4-mediated inhibition of chemotaxis to CXCL12 was even greater. Relative to the migration of untreated cells to CXCL12, the migration (mean ± SD, n = 8) of CCL4-treated pro-B, pre-B, immature, and mature B cells to CXCL12 was 37% ± 11, 31% ± 8%, 23% ± 6%, and 28% ± 11%, respectively (Figure 4Aii). Statistical analysis indicated that the decrease in chemotaxis toward CXCL12 after exposure to CCL4 was statistically highly significant for all B-cell subsets examined (P < .005, paired t test, 2-sided). CCL4-mediated inhibition of the CXCL12 chemotaxis was concentration dependent. A maximum inhibitory effect of CCL4 was observed at a concentration of 1000 ng/mL (P < .005) and was not further increased by raising the dose of CCL4 to 10 000 ng/mL (P < .005; Figure 4B). CCL4-mediated inhibition of CXCL12-induced chemotaxis was observed only when chemotaxis was run for 15 minutes. When the duration of chemotaxis was extended to 30 minutes, the desensitization/inhibition effect of CCL4 diminished (data not shown). We postulate that the decrease of the inhibitory effect is due to homologous desensitization of the CCL4-binding chemokine receptor.20 We also examined whether other CCR5-binding chemokines (eg, CCL3 and CCL5) would inhibit CXCL12-induced chemotaxis of bone marrow B cells. Both CCL3 and CCL5 mediated significant inhibition of the CXCL12-induced chemotaxis. Relative to the migration of untreated cells to CXCL12, the migration (mean ± SD, n = 4) of CCL3-treated pro-B, pre-B, immature, and mature B cells to CXCL12 was 15% ± 6%, 14% ± 13%, 23% ± 12%, and 13% ± 8%, respectively (Figure 4Ci; P < .0005) and the migration (mean ± SD, n = 4) of CCL5-treated pro-B, pre-B, immature, and mature B cells to CXCL12 was 41% ± 7%, 43% ± 12%, 42% ± 9%, and 35% ± 12%, respectively (Figure 4Cii; P < .005). In conclusion, CCL3 appeared to cause an even greater inhibition of CXCL12-induced chemotaxis than CCL4, whereas CCL5 was a less potent inhibitor than CCL4. As shown in Figure 5, CCL4 inhibition of
the CXCL12 chemotaxis was dependent on the presence of intact, cell
surface bound chemokine, as both denaturation of CCL4 and blocking of
its binding to the cell surface with neutralizing antibodies abrogated
the desensitization of CXCL12-induced chemotaxis. The inhibition was further blocked when the cells were preincubated with CCL4 for 30 minutes before the assay (Figure 5).
CCR5 receptor specificity of CCL4-mediated inhibition of CXCL12-induced chemotaxis of bone marrow B cells In the next experiments, we examined if the inhibitory effect of CCL4 was mediated by interaction with its specific receptor CCR5 or alternatively by another yet uncloned receptor present on the surface of B cells.To test this hypothesis, we used a CCR5 neutralizing antibody (clone 2D7) at a concentration that caused complete specific inhibition of CCL4-induced migration of natural killer (NK) T cells.21 As specificity controls, along with 2D7, separate aliquots of the cells were preincubated with the same amount of either nonneutralizing anti-CCR5 antibody (clone 45529) or with isotype control antibody (IgG2a). Preincubation of B cells with the CCR5 neutralizing antibody 2D7 before
the assay almost completely abrogated CCL4-mediated inhibition of
CXCL12-induced chemotaxis by all B-cell subsets (P < .05;
Figure 6). The neutralizing effect was
specific for the CCR5 receptor, because preincubation of the cells
before the assay with the same amount of either isotype control
antibody or nonneutralizing anti-CCR5 antibody did not have any effect on the CCL4-mediated inhibition of CXCL12-induced chemotaxis (Figure 6).
CCL4 does not change the level of CXCR4 expression on bone marrow B cells Previous reports indicated that chemotactic responses of cells toward chemokines could be changed by other cytokines as a result of modulation of chemokine receptor expression on the cell surface.22,23To determine whether CCL4-induced inhibition of CXCL12 chemotaxis was caused by altered cell surface expression of the CXCR4 receptor, we examined surface expression of CXCR4 on B cells after exposure to CCL4. Bone marrow B cells were preincubated with 100 or 1000 ng/mL CCL4 for 30 minutes and CXCR4 expression on these cells was compared with the expression on the cells that were incubated in medium alone. As shown in Figure 7, we found that CCL4
did not change the level of CXCR4 expression on B cells.
Non-CCR5-binding chemokines (eg, CCL19, CCL20, and CXCL13) do not inhibit CXCL12-induced chemotaxis of bone marrow B cells CCL19, CCL20, and CXCL13 were chosen because their receptors, CCR7, CCR6, or CXCR5, respectively, are expressed on developing bone marrow B cells. Moreover, these chemokines trigger strong biologic responses of bone marrow B cells at a concentration used in our experiments (data not shown; manuscript in preparation).As shown in Figure 8, none of these
chemokines affected CXCL12-induced chemotaxis of bone marrow B cells.
CCL4-mediated inhibition of CXCL12-induced activation of the MAPK pathway Because CCL4-mediated heterologous desensitization of CXCR4 receptor is independent from CXCR4 receptor internalization (Figure 7), we reasoned that CCL4-mediated signaling through CCR5 was involved. We therefore tested whether exposure of bone marrow B cells to CCL4 would affect a known CCL12/CXCR4 signaling pathway. In our evaluation, we focused on the activation of the MAPK pathway, which includes various downstream kinases, such as ERK1/2 and p38.24We showed that both CXCL12 and CCL4 can induce phosphorylation of the
MAPK pathway (Figure 9). However,
activation of the ERK1/2 and p38 was inhibited when bone marrow B cells
were stimulated sequentially, first with CCL4 and subsequently after 5 minutes with CXCL12.
These data presented further proof that CCR5 was functional on developing B cells. Secretion of CC chemokines by early- and late-lineage bone marrow B cells CC chemokines are secreted by hematopoietic progenitor cells of several lineages and thus may influence hematopoiesis in an autocrine-paracrine pathway.25 We questioned whether bone marrow B cells also could produce chemokines. Primary bone marrow B cells were cultured for 24 hours in serum-free conditions and the presence of secreted CCL3, CCL4, CCL2, CCL5, and CCL11 chemokine proteins was measured.Sorted cells (> 98.5% purity) representing early and late
stages of B-cell development secreted CCL3, CCL4, and CCL2 (Table 1). Early lineage B cells (pro-B and
pre-B) secreted (mean ± SD, n = 3) 230 ± 298 pg/mL CCL3, 134 ± 189 pg/mL CCL4, and 70 ± 36 pg/mL CCL2. Late lineage B cells
(immature B and mature B) secreted higher amounts of chemokines than
early-lineage B cells (mean ± SD, n = 3): 492 ± 354 pg/mL
CCL3, 1192 ± 341 pg/mL CCL4, and 156 ± 35 pg/mL CCL2.
Primary B cells isolated from bone marrow, however, did not
secrete CCL5 or CCL11. The differences in CCL3, CCL4, and CCL2
production between late- and early-lineage B cells were statistically
significant (P < .05).
In the present study, we show that CCR5-binding chemokines induce biologically significant responses of progenitor B cells in human bone marrow. First, we find that CCL4, similar to CXCL12,15 induces strong calcium mobilization responses of pro-B and pre-B cells. Although it is not clear how many chemokine receptor molecules are necessary to mediate calcium mobilization, other studies have shown calcium mobilization in response to CXCL12 by cell populations expressing 9% to 11% of CXCR4+ cells.18 This frequency is similar to the frequency of CCR5+ cells detected in our analyses of bone marrow B cells. CCL4 did not cause calcium mobilization of either immature or mature B cells, although the level of CCR5 expression on these cell populations was comparable to pro-B and pre-B cells. The mechanism(s) underlying this difference in responsiveness is presently unknown but may be explained by G-protein-coupled receptor-related regulatory mechanisms,26,27 which might be operational at distinct stages of cellular development. As mentioned above, progenitor B cells show strong calcium mobilization responses to both CXCL12 and CCL4. However, when pre-B cells are first stimulated with CCL4 and then subsequently restimulated with CXCL12, no calcium mobilization is observed in response to CXCL12. It is noteworthy that such cross-desensitization is not observed when cells are first stimulated with CXCL12. Interestingly, a similar pattern of cross-regulation of CXCR4 by CCR2 has been described in 293T cells cotransfected with CCR2 and CXCR4.28 Two types of desensitization are known: homologous and heterologous. Homologous desensitization is specific for a receptor and its ligands.29 Heterologous desensitization refers to a process whereby ligand-induced activation of one chemokine receptor results in the desensitization of different receptors.30 The cross-desensitization of CXCR4 by CCL4 is of the heterologous type because CXCL12 is considered to be the exclusive ligand for CXCR4.31 Moreover, we show that this cross-regulation of CXCR4 on B-cell progenitors is dependent on signaling through CCR5 (Figure 6). Receptor desensitization occurs during short-term (seconds to minutes) exposure of cells to activating ligands. The termination of signaling is mediated by uncoupling of activated receptors from G-proteins. The mechanisms involved in the cross-desensitization of chemokine receptors occur at different levels and include cross-phosphorylation of the receptor as well as cross-regulation at a site distal to the receptor/G-protein coupling involving downstream signaling pathways (eg, phospholipase C).32 In contrast, receptor internalization and subsequent down-regulation is due to loss of receptors from the cell surface and requires longer exposure (30 minutes to hours) of cells to ligands. In separate experiments we determined that CCL4 does, in fact, bind to
B cells (data not shown) but does not cause internalization of CXCR4
(Figure 7). Thus, we speculate that the mechanism of CCL4-mediated
cross-desensitization of CXCR4 might be dependent on
cross-phosphorylation of CXCR4 or a further downstream signaling event
such as phosphorylation of phospholipase C This cross-desensitization has biologic consequences, because we show that inhibition of CXCL12-induced responses by CCR5-binding chemokines could also be measured by inhibition of chemotaxis. Of note is the absence of inhibition when the cells are exposed to CCL4 for 30 minutes before the chemotaxis assay (Figure 5). We speculate that prior exposure to CCL4 in the range of 30 minutes effects down-regulation of the CCR5 receptor resulting primarily from internalization of the receptor.35,36 One of the most important functions of chemokines and their receptors is the regulation of directional migration of blood cells within secondary lymphoid organs and tissues.13,37 In specific tissue compartments, cells are exposed to multiple chemokines presented in the context of very complex dimensional and temporal patterns. Therefore, cells must use chemokine receptors sequentially to move along different chemotactic gradients. The switch from the use of one type of receptor to another could well be determined by the capacity of the first to undergo ligand-induced desensitization.38 Such mechanisms are likely to be operational in the retention or correct positioning of progenitor cells in the extravascular compartment of the bone marrow. In this regard, increasing evidence suggests that the CXCR4/CXCL12 axis plays an important role in retaining B-cell precursors within the supportive niches of bone marrow for further maturation. However, progenitor B cells simultaneously receive signals mediated by a whole range of molecules (cytokines, chemokines, adhesion molecules) expressed by various cell types (stroma-, lymphoid-, and myeloid-lineage cells) in the bone marrow microenvironment.6,25 In this regard, bone marrow developing B cells could provide these signals in an autocrine manner, as they produce numerous CC chemokines in vitro (Table 1). Conceivably, some signals have an additive effect, whereas others may have a negative effect on target cells. Short-lasting desensitization of B-cell responses could enable progenitor B cells to temporarily "escape" CXCL12-induced retention in developmentally specific microenvironmental niches. This process would then allow the progenitor B cells to respond to other migratory gradients and to move toward sinusoids and into the circulation. Had the desensitization been of longer duration, it could have eventually led to the premature release of progenitor cells from the bone marrow as occurs following the infusion of CCL3-mimicking compounds,39 which also signal through CCR5. Based on the results of our studies on bone marrow-derived B cells, we postulate that cross-desensitization of CXCR4 through signaling of CCR5 is relevant to B lymphopoiesis. Through desensitization or modulation of CXCR4 function or both, CCR5-binding chemokines could influence the multistep processes of movement and maturation of progenitor B cells in the extravascular compartment of bone marrow.8,9
The authors are very grateful to Drs John Manis and Mark Shlomchik for their critical review of the manuscript.
Submitted January 30, 2002; accepted May 17, 2002.
Prepublished online as Blood First Edition Paper, May 31, 2002; DOI 10.1182/blood-2002-01-0248.
Supported by National Institutes of Health grant P50HL54516.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Leslie E. Silberstein, Joint Program in Transfusion Medicine, Harvard Medical School, Children's Hospital Boston, Bader 410, 300 Longwood Ave, Boston, MA 02115; e-mail: leslie.silberstein{at}tch.harvard.edu.
1. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 1994;12:593-633[CrossRef][Medline] [Order article via Infotrieve]. 2. Melchers F, Rolink AG, Schaniel C. The role of chemokines in regulating cell migration during humoral immune responses. Cell. 1999;99:351-354[CrossRef][Medline] [Order article via Infotrieve].
3.
Cyster JG.
Chemokines and cell migration in secondary lymphoid organs.
Science.
1999;286:2098-2102
4.
Rollins BJ.
Chemokines.
Blood.
1997;90:909-928 5. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217-242[CrossRef][Medline] [Order article via Infotrieve].
6.
LeBien TW.
Fates of human B-cell precursors.
Blood.
2000;96:9-23 7. Osmond DG, Park YH, Jacobsen K. B cell precursors in bone marrow: in vivo proliferation, localization, stimulation by activated macrophages and implications for oncogenesis. Curr Top Microbiol Immunol. 1988;141:2-10[Medline] [Order article via Infotrieve].
8.
Osmond DG, Kim N, Manoukian R, Phillips RA, Rico-Vargas SA, Jacobsen K.
Dynamics and localization of early B-lymphocyte precursor cells (pro-B cells) in the bone marrow of scid mice.
Blood.
1992;79:1695-1703 9. Jacobsen K, Osmond DG. Microenvironmental organization and stromal cell associations of B lymphocyte precursor cells in mouse bone marrow. Eur J Immunol. 1990;20:2395-2404[Medline] [Order article via Infotrieve]. 10. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635-638[CrossRef][Medline] [Order article via Infotrieve].
11.
Ma Q, Jones D, Borghesani PR, et al.
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.
Proc Natl Acad Sci U S A.
1998;95:9448-9453 12. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999;10:463-471[CrossRef][Medline] [Order article via Infotrieve]. 13. Ansel KM, Cyster JG. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol. 2001;13:172-179[CrossRef][Medline] [Order article via Infotrieve]. 14. D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol. 1997;27:1788-1793[Medline] [Order article via Infotrieve].
15.
Honczarenko M, Douglas RS, Mathias C, Lee B, Ratajczak MZ, Silberstein LE.
SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells.
Blood.
1999;94:2990-2998 16. Fedyk ER, Ryyan DH, Ritterman I, Springer TA. Maturation decreases responsiveness of human bone marrow B lineage cells to stromal-derived factor 1 (SDF-1). J Leukoc Biol. 1999;66:667-673[Abstract].
17.
Lee B, Sharron M, Blanpain C, et al.
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.
J Biol Chem.
1999;274:9617-9626
18.
Doranz BJ, Orsini MJ, Turner JD, et al.
Identification of CXCR4 domains that support coreceptor and chemokine receptor functions.
J Virol.
1999;73:2752-2761 19. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT. Active movement of T cells away from a chemokine. Nat Med. 2000;6:543-548[CrossRef][Medline] [Order article via Infotrieve]. 20. Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, Cullen MG. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO J. 1997;16:4606-4616[CrossRef][Medline] [Order article via Infotrieve].
21.
Campbell JJ, Qin S, Unutmaz D, et al.
Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire.
J Immunol.
2001;166:6477-6482
22.
Ogata M, Zhang Y, Wang Y, et al.
Chemotactic response toward chemokines and its regulation by transforming growth factor-beta1 of murine bone marrow hematopoietic progenitor cell-derived different subset of dendritic cells.
Blood.
1999;93:3225-3232
23.
Dieu-Nosjean MC, Massacrier C, Vanbervliet B, Fridman WH, Caux C.
IL-10 Induces CCR6 expression during Langerhans cell development while IL-4 and IFN-gamma suppress it.
J Immunol.
2001;167:5594-5602 24. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 1999;11:211-218[CrossRef][Medline] [Order article via Infotrieve].
25.
Majka M, Janowska-Wieczorek A, Ratajczak J, et al.
Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner.
Blood.
2001;97:3075-3085
26.
Reif K, Cyster JG.
RGS molecule expression in murine B lymphocytes and ability to down-regulate chemotaxis to lymphoid chemokines.
J Immunol.
2000;164:4720-4729
27.
Moratz C, Kang VH, Druey KM, et al.
Regulator of G protein signaling 1 (RGS1) markedly impairs Gi alpha signaling responses of B lymphocytes.
J Immunol.
2000;164:1829-1838
28.
Lee B, Doranz BJ, Rana S, et al.
Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4.
J Virol.
1998;72:7450-7458
29.
Aragay AM, Mellado M, Frade JM, et al.
Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization mediated by the G protein-coupled receptor kinase 2.
Proc Natl Acad Sci U S A.
1998;95:2985-2990
30.
Ali H, Richardson RM, Haribabu B, Snyderman R.
Chemoattractant receptor cross-desensitization.
J Biol Chem.
1999;274:6027-6030 31. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127[CrossRef][Medline] [Order article via Infotrieve].
32.
Richardson RM, Pridgen BC, Haribabu B, Snyderman R.
Regulation of the human chemokine receptor CCR1: cross-regulation by CXCR1 and CXCR2.
J Biol Chem.
2000;275:9201-9208
33.
Haribabu B, Richardson RM, Fisher I, et al.
Regulation of human chemokine receptors CXCR4: role of phosphorylation in desensitization and internalization.
J Biol Chem.
1997;272:28726-28731
34.
Richardson RM, Ali H, Tomhave ED, Haribabu B, Snyderman R.
Cross-desensitization of chemoattractant receptors occurs at multiple levels: evidence for a role for inhibition of phospholipase C activity.
J Biol Chem.
1995;270:27829-27833
35.
Forster R, Kremmer E, Schubel A, et al.
Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation.
J Immunol.
1998;160:1522-1531
36.
Amara A, Gall SL, Schwarzt O, et al.
HIV coreceptor downregulation as antiviral principle: SDF-1alpha dependent internalization of the chemokine receptor CXCR-4 contributes to inhibition of HIV replication.
J Exp Med.
1997;186:139-146 37. Jung S, Littman DR. Chemokine receptors in lymphoid organ homeostasis. Curr Opin Immunol. 1999;11:319-325[CrossRef][Medline] [Order article via Infotrieve].
38.
Foxman EF, Campbell JJ, Butcher EC.
Multistep navigation and the combinatorial control of leukocyte chemotaxis.
J Cell Biol.
1997;139:1349-1360
39.
Lord BI, Woolford LB, Wood LM, et al.
Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha.
Blood.
1995;85:3412-3415
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Basu and H. E. Broxmeyer CCR5 Ligands Modulate CXCL12-Induced Chemotaxis, Adhesion, and Akt Phosphorylation of Human Cord Blood CD34+ Cells J. Immunol., December 1, 2009; 183(11): 7478 - 7488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Vanpouille, A. Biancotto, A. Lisco, and B. Brichacek Interactions between Human Immunodeficiency Virus Type 1 and Vaccinia Virus in Human Lymphoid Tissue Ex Vivo J. Virol., November 15, 2007; 81(22): 12458 - 12464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Rookmaaker, M. C. Verhaar, H. C. de Boer, R. Goldschmeding, J. A. Joles, H. A. Koomans, H.-J. Grone, and T. J. Rabelink Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo Am J Physiol Renal Physiol, August 1, 2007; 293(2): F624 - F630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Al-Alwan, Q. Du, S. Hou, B. Nashed, Y. Fan, X. Yang, and A. J. Marshall Follicular Dendritic Cell Secreted Protein (FDC-SP) Regulates Germinal Center and Antibody Responses J. Immunol., June 15, 2007; 178(12): 7859 - 7867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-T. Choi, M. Kaul, S. Kumar, J. Wang, I. M. K. Kumar, C.-Z. Dong, J. An, S. A. Lipton, and Z. Huang Neuronal Apoptotic Signaling Pathways Probed and Intervened by Synthetically and Modularly Modified (SMM) Chemokines J. Biol. Chem., March 9, 2007; 282(10): 7154 - 7163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vianello, N. Papeta, T. Chen, P. Kraft, N. White, W. K. Hart, M. F. Kircher, E. Swart, S. Rhee, G. Palu, et al. Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control. J. Immunol., March 1, 2006; 176(5): 2902 - 2914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Ratajczak RGS16 "tightens the reins" on CXCR4 Blood, November 1, 2005; 106(9): 2928 - 2929. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Wysocki, A. Panoskaltsis-Mortari, B. R. Blazar, and J. S. Serody Leukocyte migration and graft-versus-host disease Blood, June 1, 2005; 105(11): 4191 - 4199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Le, M. Honczarenko, A. M. Glodek, D. K. Ho, and L. E. Silberstein CXC Chemokine Ligand 12-Induced Focal Adhesion Kinase Activation and Segregation into Membrane Domains Is Modulated by Regulator of G Protein Signaling 1 in Pro-B Cells J. Immunol., March 1, 2005; 174(5): 2582 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wysoczynski, R. Reca, J. Ratajczak, M. Kucia, N. Shirvaikar, M. Honczarenko, M. Mills, J. Wanzeck, A. Janowska-Wieczorek, and M. Z. Ratajczak Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient Blood, January 1, 2005; 105(1): 40 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jones CCR2: holding B cells back Blood, August 15, 2004; 104(4): 911 - 912. [Full Text] [PDF]
|
|
|
|
|
|
L. Flaishon, S. Becker-Herman, G. Hart, Y. Levo, W. A. Kuziel, and I. Shachar Expression of the chemokine receptor CCR2 on immature B cells negatively regulates their cytoskeletal rearrangement and migration Blood, August 15, 2004; 104(4): 933 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Wysocki, S. B. Burkett, A. Panoskaltsis-Mortari, S. L. Kirby, A. D. Luster, K. McKinnon, B. R. Blazar, and J. S. Serody Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning J. Immunol., July 15, 2004; 173(2): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Corcione, N. Arduino, E. Ferretti, L. Raffaghello, S. Roncella, D. Rossi, F. Fedeli, L. Ottonello, L. Trentin, F. Dallegri, et al. CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells Clin. Cancer Res., February 1, 2004; 10(3): 964 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reca, D. Mastellos, M. Majka, L. Marquez, J. Ratajczak, S. Franchini, A. Glodek, M. Honczarenko, L. A. Spruce, A. Janowska-Wieczorek, et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1 Blood, May 15, 2003; 101(10): 3784 - 3793. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
to initiate the migration of the lymphocytes
